Oct. 25 at 9:25 PM
$OTLK You don't even know what your invested in. They have zero pipeline. Here is upcoming competition in a crowded space. Late/early-stage wet AMD drugs: ABBV-RGX-314 (Regenxbio/AbbVie, Ph3), ADVM-022 Ixo-vec (Adverum, Ph3), Tarcocimab KSI-301 (Kodiak, Ph3), 4D-150 (4DMT, Ph3), GB-102 (Graybug, Ph2b), OPT-302 (Opthea, Ph3 combo VEGF-C/D), EYP-1901 (EyePoint, Ph2), RGX-314 suprachoroidal (Regenxbio, Ph2), Faricimab Vabysmo (Roche, approved), Susvimo PDS (Roche, approved/relaunch). Some can eliminate injections altogether.